Clinical Trial

A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
Trial Details
NCT Number NCT07615270
Lead Sponsor Stanford University
Conditions AL Amyloidosis
Enrollment 5 participants
Start Date 2026-07
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-29